Stay updated on Pembrolizumab in Refractory Meningioma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Refractory Meningioma Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Revision label updated to v3.5.0; the previous v3.4.3 label was removed.
    Difference
    0.1%
    Check dated 2026-03-21T16:48:38.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    29 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-07T08:49:00.000Z thumbnail image
  5. Check
    50 days ago
    Change Detected
    Summary
    The visible change is a minor revision label updated from v3.4.1 to v3.4.2; no alterations to the study content, eligibility criteria, or essential page functionality are evident. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-13T17:31:08.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-06T11:35:27.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The page shows a minor version update from v3.4.0 to v3.4.1. There are no observed changes to core study content, eligibility criteria, or outcomes; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-05T12:26:05.000Z thumbnail image
  8. Check
    66 days ago
    Change Detected
    Summary
    Glossary is now shown on the page, and QC-related metadata has been updated to display 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', replacing previous wording/capitalization. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-29T06:28:52.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Refractory Meningioma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.